Skip to content
RushPR News – Lifestyle
Author:
AlzeCure Pharma
Final Outcome of AlzeCure’s Rights Issue
July 2, 2026
AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project
July 1, 2026
Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026
June 29, 2026
Positive Results From The Phase Ib Clinical Study of NeuroRestore ACD856, Under Development for Alzheimer’s
June 16, 2026
AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer’s Project
June 9, 2026
Notice To Annual General Meeting in AlzeCure Pharma AB
May 26, 2026
AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain
May 19, 2026
AlzeCure Pharma to Present at Redeye Investor Forum Online on May 21
May 13, 2026
AlzeCure Pharma to Present at ABG Investor Days on May 21
May 13, 2026
New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain
May 6, 2026
1
2
Next Page
→